Please assess the completion status of the following clinical trial:

Trial Title: Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of MM by International Myeloma Working Group Criteria~* In first or second complete or partial remission or stable refractory but not actively progressing myeloma according to the classifications provided by The Center for International Blood \& Marrow Transplant Research~* Received at least 2 cycles of lenalidomide therapy~* Patients with MM scheduled to undergo stem cell harvest for possible allogeneic stem cell transplant (ASCT)~* At least 2 weeks since last exposure to lenalidomide~* Eastern Cooperative Oncology Group performance status of 0 or 1~* Prior to the start of mobilization:~  * white blood cell count \>/= 2.5 x 10\^9/L~ * absolute neutrophil count \>/= 1.2 x 10\^9/L~ * platelet count \>/=100 x 10\^9/L~ * creatinine clearance \>/= 30mL/minute~* If childbearing potential, must either agree to complete abstinence from heterosexual intercourse or effective means of contraception during stem cell mobilization; female patients will undergo pregnancy test prior to stem cell mobilization therapy~Exclusion Criteria:~* Had prior autologous or allogeneic transplantation~* Received pegfilgrastim within 3 weeks or G-CSF within 14 days of first dose of G-CSF for mobilization~* Failed previous hematopoietic stem cell collections or collection attempts~* Received radiation therapy to the pelvic area~* Received lenalidomide within 2 weeks of first dose of G-CSF for mobilization~* Had received experimental therapy within 4 weeks of enrolling in study~* Current or prior history of other malignancies, excluding basal cell carcinoma of the skin

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive G-CSF SC QD on days 1-4.
- Arm II (Type: EXPERIMENTAL): Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.

Based on this trial design, predict the completion outcome and termination type (if applicable).